nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

D A Yardley, R Coleman, P Conte, J Cortes, A Brufsky, M Shtivelband, R Young, C Bengala, H Ali, J Eakel, A Schneeweiss, L de la Cruz-Merino, S Wilks, J O'Shaughnessy, S Glück, H Li, J Miller, D Barton, N Harbeck, tnAcity investigators, D A Yardley, R Coleman, P Conte, J Cortes, A Brufsky, M Shtivelband, R Young, C Bengala, H Ali, J Eakel, A Schneeweiss, L de la Cruz-Merino, S Wilks, J O'Shaughnessy, S Glück, H Li, J Miller, D Barton, N Harbeck, tnAcity investigators

Abstract

Background: Metastatic triple-negative breast cancer (mTNBC) has a poor prognosis and aggressive clinical course. tnAcity evaluated the efficacy and safety of first-line nab-paclitaxel plus carboplatin (nab-P/C), nab-paclitaxel plus gemcitabine (nab-P/G), and gemcitabine plus carboplatin (G/C) in patients with mTNBC.

Patients and methods: Patients with pathologically confirmed mTNBC and no prior chemotherapy for metastatic BC received (1 : 1 : 1) nab-P 125 mg/m2 plus C AUC 2, nab-P 125 mg/m2 plus G 1000 mg/m2, or G 1000 mg/m2 plus C AUC 2, all on days 1, 8 q3w. Phase II primary end point: investigator-assessed progression-free survival (PFS); secondary end points included overall response rate (ORR), overall survival (OS), percentage of patients initiating cycle 6 with doublet therapy, and safety.

Results: In total, 191 patients were enrolled (nab-P/C, n = 64; nab-P/G, n = 61; G/C, n = 66). PFS was significantly longer with nab-P/C versus nab-P/G [median, 8.3 versus 5.5 months; hazard ratio (HR), 0.59 [95% CI, 0.38-0.92]; P = 0.02] or G/C (median, 8.3 versus 6.0 months; HR, 0.58 [95% CI, 0.37-0.90]; P = 0.02). OS was numerically longer with nab-P/C versus nab-P/G (median, 16.8 versus 12.1 months; HR, 0.73 [95% CI, 0.47-1.13]; P = 0.16) or G/C (median, 16.8 versus 12.6 months; HR, 0.80 [95% CI, 0.52-1.22]; P = 0.29). ORR was 73%, 39%, and 44%, respectively. In the nab-P/C, nab-P/G, and G/C groups, 64%, 56%, and 50% of patients initiated cycle 6 with a doublet. Grade ≥3 adverse events were mainly hematologic.

Conclusions: First-line nab-P/C was active in mTNBC and resulted in a significantly longer PFS and improved risk/benefit profile versus nab-P/G or G/C.

Figures

Figure 1.
Figure 1.
Kaplan–Meier curve of (A) progression-free survival (PFS) and (B) overall survival (OS). G/C, gemcitabine plus carboplatin; HR, hazard ratio; nab-P/C, nab-paclitaxel plus carboplatin; nab-P/G, nab-paclitaxel plus gemcitabine.
Figure 2.
Figure 2.
Best response.

References

    1. American Cancer Society. Breast Cancer Facts & Figures 2015-2016. Atlanta, GA: American Cancer Society 2015.
    1. Hudis CA, Gianni L.. Triple-negative breast cancer: an unmet medical need. Oncologist 2011; 16(Suppl 1): 1–11.
    1. Bauer KR, Brown M, Cress RD. et al. Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype. Cancer 2007; 109(9): 1721–1728.
    1. Liedtke C, Mazouni C, Hess KR. et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26(8): 1275–1281.
    1. Dent R, Trudeau M, Pritchard KI. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13(15 Pt 1): 4429–4434.
    1. Lin NU, Claus E, Sohl J. et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008; 113(10): 2638–2645.
    1. Lehmann BD, Bauer JA, Chen X. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121(7): 2750–2767.
    1. Chacón RD, Costanzo MV.. Triple-negative breast cancer. Breast Cancer Res 2010; 12(Suppl 2): S3.
    1. O'Shaughnessy J, Osborne C, Pippen JE. et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364(3): 205–214.
    1. O'Shaughnessy J, Schwartzberg L, Danso MA. et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 2014; 32(34): 3840–3847.
    1. Karginova O, Siegel MB, Van Swearingen AE. et al. Efficacy of carboplatin alone and in combination with ABT888 in intracranial murine models of BRCA-mutated and BRCA-wild-type triple-negative breast cancer. Mol Cancer Ther 2015; 14(4): 920–930.
    1. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Breast cancer. version 2.2017. (18 June 2018, date last accessed).
    1. Cardoso F, Costa A, Senkus E. et al. 3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol 2017; 28(1): 16–33.
    1. Sledge GW, Neuberg D, Bernardo P. et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003; 21(4): 588–592.
    1. Rugo HS, Barry WT, Moreno-Aspitia A. et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (alliance). J Clin Oncol 2015; 33(21): 2361–2369.
    1. Hamilton E, Kimmick G, Hopkins J. et al. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. Clin Breast Cancer 2013; 13(6): 416–420.
    1. Lobo C, Lopes G, Baez O. et al. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2010; 123(2): 427–435.
    1. Yardley DA, Brufsky A, Coleman RE. et al. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials 2015; 16(1): 575.
    1. Wahba HA, El-Hadaad HA.. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med 2015; 12(2): 106–116.
    1. Egger SJ, Willson ML, Morgan J. et al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2017; 6: CD003374..
    1. Tutt A, Ellis P, Kilburn L. Abstract S3-01: the TNT trial: a randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple-negative or BRCA1/2 breast cancer. Cancer Res 2015; 75.
    1. Hu XC, Zhang J, Xu BH. et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2015; 16(4): 436–446.
    1. Gluz O, Nitz U, Christgen M. et al. Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial. J Clin Oncol 2015; 15(33 Suppl): 1032.
    1. Yao H, He G, Yan S. et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget 2017; 8(1): 1913–1924.
    1. Miles D, Diéras V, Cortés J. et al. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 2013; 24(11): 2773–2780.
    1. Robson M, Im SA, Senkus E. et al. Olaparib for metastatic breast cancer patients with a germline BRCA mutation. N Engl J Med 2017; 377(6): 523–533.
    1. Adams S, Diamond JR, Hamilton EP. et al. Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). J Clin Oncol 2016; 34(Suppl 15): 1009.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner